---
figid: PMC4591813__zbc0431527200005
figtitle: ErbB3 in RAF-inhibited mutant BRAF melanoma cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4591813
filename: zbc0431527200005.jpg
figlink: /pmc/articles/PMC4591813/figure/F5/
number: F5
caption: Schematic of targeting compensatory/adaptive activation of ErbB3 in RAF-inhibited
  mutant BRAF melanoma cells. Seribantumab and pertuzumab prevent the activation of
  the ErbB3 pathway induced by fibroblast- and CAF-derived NRG1 following vemurafenib
  treatment in mutant BRAF melanoma cells.
papertitle: Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling
  in Mutant BRAF Melanoma.
reftext: Claudia Capparelli, et al. J Biol Chem. 2015 Oct 2;290(40):24267-24277.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9393616
figid_alias: PMC4591813__F5
figtype: Figure
redirect_from: /figures/PMC4591813__F5
ndex: 7ce24520-de8d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4591813__zbc0431527200005.html
  '@type': Dataset
  description: Schematic of targeting compensatory/adaptive activation of ErbB3 in
    RAF-inhibited mutant BRAF melanoma cells. Seribantumab and pertuzumab prevent
    the activation of the ErbB3 pathway induced by fibroblast- and CAF-derived NRG1
    following vemurafenib treatment in mutant BRAF melanoma cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KAT2B
  - ERBB3
  - ERBB2
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - NRG1
---
